Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded a decrease of -69.91%. However, over the last six months, the performance has been stronger by -76.71%. The price of LXEO decreased -33.33% over the last 30 days. And in the last five days, it has fallen by -15.20%.
Lexeo Therapeutics Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $19.50 on 07/11/24, while the lowest price for the same period was registered at $1.45 on 04/07/25.
52-week price history of LXEO Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Lexeo Therapeutics Inc’s current trading price is -89.85% away from its 52-week high, while its distance from the 52-week low is 36.55%. The stock’s price range during this period has varied between$1.45 and $19.50. The Lexeo Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.86 million for the day, a figure considerably higher than their average daily volume of 0.69 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Lexeo Therapeutics Inc (LXEO) has experienced a quarterly decline of -69.01% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 65.74M and boasts a workforce of 72 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.0251, with a change in price of -5.8000. Similarly, Lexeo Therapeutics Inc recorded 530,006 in trading volume during the last 100 days, posting a change of -74.55%.
LXEO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for LXEO stands at 0.08. Similarly, the long-term debt-to-equity ratio is also 0.06.
LXEO Stock Stochastic Average
As of today, Lexeo Therapeutics Inc’s raw stochastic average for the last 50 days stands at 11.55%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 16.88%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 22.93% and 20.45%, respectively.
